Cirtuvivint (SM08502) is an orally bioavailable, potent inhibitor of CDC-like kinases (CLKs) used in research. It has been investigated in preclinical models, including in vitro studies of splicing modulation and in vivo models of inflammatory diseases such as arthritis.